新型冠状病毒(COVID-19)精准药物设计——基于病毒感染人体细胞进程的初步探讨
CSTR:
作者:
中图分类号:

R45;F763

基金项目:

河北省社会科学基金项目一般项目(HB19SH020)


Precise Drug Design for the Novel Coronavirus (COVID-19): A Preliminary Prediction on the Process of Virus Infection in Human Cells
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [23]
  • |
  • 相似文献 [2]
  • | | |
  • 文章评论
    摘要:

    针对新型冠状病毒(COVID-19)精准药物研发问题,围绕COVID-19感染人体细胞的基本步骤,如病毒表面蛋白结合人体细胞受体、病毒穿透细胞膜、病毒脱壳、病毒核酸释放与复制、病毒蛋白表达与成熟、新病毒装配等,预测针对这些环节设计小分子化合物、抗体或反义RNA片段等,进而抑制病毒关键分子如Spike蛋白、RdRp聚合酶、3CL水解酶及多种关键的RNA基因序列,最终达到精准治疗新型冠状病毒感染的目的。

    Abstract:

    In view of promoting the research and development of precision drugs for the novel coronavirus COVID-19,this paper focuses on the basic steps of COVID-19 infection in human cells, such as viral surface protein binding to human cell receptor, viral penetration into cell membrane, viral uncoating, release and replication of viral nucleic acids, expression and maturation of viral proteins, new virus assembly. Based on these steps, it is expected that small molecule compounds, antibodies or antisense RNA fragments could be designed to prevent the key viral molecules such as Spike protein, RdRp polymerase, 3CL hydrolase and a variety of key RNA genes, so as to achieve the goal of accurate treatment of COVID-19 infection.

    参考文献
    [1] WANG F S, ZHANG C. What to do next to Control the 2019-nCoV Epidemic? [J]. Lancet, 2020, 395(10222): 391-393.
    [2] LIU Z J, BAI J, LIU F L, et al. Focus on the Therapeutic Efficacy of 3BNC117 against HIV-1: In Vitro Studies, in Vivo Studies, Clinical Trials and Challenges [J]. International Immunopharmacology, 2017, 52: 44-50.
    [3] HOU H, WANG J Z, LIU B G, et al. Pin1 Liberates the Human Immunodeficiency Virus Type-1(HIV-1): Must we Stop it? [J]. Gene, 2015, 565(1): 9-14.
    [4] PARASKEVIS D, KOSTAKI E G, MAGIORKINIS G, et al. Full-Genome Evolutionary Analysis of the Novel Corona virus (2019-nCoV) Rejects the Hypothesis of Emergence as a Result of a Recent Recombination Event [J]. Infect Genet Evol, 2020, 79: 104212.
    [5] MORSE J S, LALONDE T, XU S, et al. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV [J]. Chembiochem, 2020, 21(5): 730-738.
    [6] CHEN J. Pathogenicity and Transmissibility of 2019-nCoV-A Quick Overview and Comparison with other Emerging Viruses [J]. Microbes Infect, 2020, 22(2): 69-71.
    [7] ZHOU P, YANG X L, WANG X G, et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin [J]. Nature, 2020, 579(7798): 270-273.
    [8] CHAN J F, KOK K H, ZHU Z, et al. Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan [J]. Emerg Microbes Infect, 2020, 9(1): 221-236.
    [9] CHEN Y, LIU Q, GUO D. Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis[J]. J Med Virol, 2020, 92(4): 418-423.
    [10] PROCHNOW H, ROX K, BIRUDUKOTA N V S, et al. Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis [J]. Journal of Virology, 2020, 94(2): e01471-01419.
    [11] HUANG S M, GU J J, YE J, et al. Benzoxazine Monomer Derived Carbon Dots as a Broad-Spectrum Agent to Block Viral Infectivity [J]. Journal of Colloid and Interface Science, 2019, 542: 198-206.
    [12] GAO Y N, TAI W B, WANG N, et al. Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors [J]. Viruses-Basel, 2019, 11(11): 1019.
    [13] WU Y, PONS V, NOEL R, et al. DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses [J]. Acs Medicinal Chemistry Letters, 2019, 10(8): 1140-1147.
    [14] DU L Y, HE Y X, ZHOU Y S, et al. The Spike Protein of SARS-CoV - a Target for Vaccine and Therapeutic Development [J]. Nature Reviews Microbiology, 2009, 7(3): 226-236.
    [15] YU P, HU B, SHI Z L, et al. Geographical Structure of Bat SARS-related Coronaviruses [J]. Infection Genetics and Evolution, 2019, 69: 224-229.
    [16] JI W, WANG W, ZHAO X, et al. Cross-species Transmission of the Newly Identified Coronavirus 2019-nCoV [J]. J Med Virol, 2020, 92(4): 433-440.
    [17] CHEN L, LIU W, ZHANG Q, et al. RNA based mNGS Approach Identifies a Novel Human Coronavirus from two Individual Pneumonia Cases in 2019 Wuhan Outbreak [J]. Emerg Microbes Infect, 2020, 9(1): 313-319.
    [18] MADHVI A, HINGANE S, SRIVASTAV R, et al. A Screen for Novel Hepatitis C Virus RdRp Inhibitor Identifies a Broad-Spectrum Antiviral Compound [J]. Scientific Reports, 2017, 7: 5816.
    [19] YAO X G, GUO S X, WU W Y, et al. Q63, a Novel DENV2 RdRp Non-Nucleoside Inhibitor, Inhibited DENV2 Replication and Infection [J]. Journal of Pharmacological Sciences, 2018, 138(4): 247-256.
    [20] RITTENHOUSE K D, JOHNSON T R, VICINI P, et al. RTP801 Gene Expression Is Differentially Upregulated in Retinopathy and Is Silenced by PF-04523655, a 19-Mer siRNA Directed Against RTP801[J]. Investigative Ophthalmology & Visual Science, 2014, 55(3): 1232-1240.
    [21] NUR S M, HASAN M A, AL AMIN M, et al. Design of Potential RNAi (miRNA and siRNA) Molecules for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Gene Silencing by Computational Method [J]. Interdisciplinary Sciences-Computational Life Sciences, 2015, 7(3): 257-265.
    [22] JO S, KIM S, SHIN D H, et al. Inhibition of SARS-CoV 3CL Protease by flavonoids [J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35(1): 145-151.
    [23] YOSHIZAWA S, HATTORI Y, KOBAYASHI K, et al. Evaluation of an Octahydroisochromene Scaffold used as a Novel SARS 3CL Protease Inhibitor [J]. Bioorganic & Medicinal Chemistry, 2020, 28(4): 115273.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

王敬章,张瑞英,白净,张玉华,张向阳,刘睿.新型冠状病毒(COVID-19)精准药物设计——基于病毒感染人体细胞进程的初步探讨[J].河北工程大学自然版,2020,37(1):109-112

复制
分享
文章指标
  • 点击次数:683
  • 下载次数: 840
  • HTML阅读次数: 0
  • 引用次数: 0
历史
  • 收稿日期:2020-02-15
  • 在线发布日期: 2020-04-30
文章二维码